Filing Flows › Corcept Therapeutics (CORT) › Guidance & outlook
Corcept Therapeutics (CORT) guidance and outlook
Corcept Therapeutics (CORT) reaffirmed its guidance on Nov 3, 2026: Revenue $1.1B–$1.2B for FY2026. Corcept Therapeutics' 10-Q filed Nov 3, 2026 makes 8 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.1B–$1.2B | reaffirmed |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- Our policy is that no patient with hypercortisolism will be denied access to our medications for financial reasons.
- We are conducting a study in patients with ALS to determine whether dose titration will reduce instances of abdominal pain and allow more patients to benefit from dazucorilant.
- We anticipate this provision will limit the revenue we receive from Medicare patients and may materially reduce our profits in 2026 and beyond.
- We do not expect either of these provisions to significantly affect our condensed consolidated financial statements.
- Product Revenue, Net – Product Revenue, Net, or Net product revenue, is gross product revenue from sales to our customers less deductions for estimated government rebates and chargebacks, patient assistance programs, discounts provided to our distributors for prompt payment, distribution and administrative fees, voucher assistance and reserves for expected returns.
- We expect our research and development expense in 2026 to be approximately the same as in 2025 , as we advance our clinical programs and initiate new clinical trials, offset by decreased expenses due to clinical programs that are nearing completion and as the cost of manufacturing Lifyorli after regulatory approval is no longer recorded as research and development expenses.
- We expect our selling, general and administrative expense to be higher in 2026 than in 2025 due to increased commercial and administrative activities to support our increased sales and marketing efforts.
- Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise
Corcept Therapeutics' latest quarter
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
Did Corcept Therapeutics raise or lower its guidance?
Corcept Therapeutics (CORT) reaffirmed its guidance on Nov 3, 2026: Revenue $1.1B–$1.2B for FY2026.
What does Corcept Therapeutics expect?
Our policy is that no patient with hypercortisolism will be denied access to our medications for financial reasons. We are conducting a study in patients with ALS to determine whether dose titration will reduce instances of abdominal pain and allow more patients to benefit from dazucorilant. We anticipate this provision will limit the revenue we receive from Medicare patients and may materially reduce our profits in 2026 and beyond.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.